Halozyme Therapeutics Inc (HALO)
Number of days of payables
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ —
= —
The data for Halozyme Therapeutics Inc's number of days of payables spanning from March 31, 2020, to December 31, 2024, indicates that specific information on payables days is not available. The unavailable data may suggest that the company does not disclose or calculate this metric in its financial reporting during the specified periods.
This lack of data on the number of days of payables makes it challenging to assess how quickly or slowly the company pays its outstanding obligations to suppliers, a crucial aspect of managing working capital efficiency and relationships with vendors. In the absence of this information, it becomes difficult to analyze the effectiveness of Halozyme's payment policies and their impact on cash flow management.
It is important for investors and stakeholders to consider this limitation when evaluating the company's financial health, as managing payables effectively plays a significant role in maintaining liquidity and optimizing cash flow within a business. The absence of this specific ratio underscores the need for additional information or alternative metrics to comprehensively assess Halozyme's financial performance and operational efficiency related to its payment practices.
Peer comparison
Dec 31, 2024